Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection

J Antimicrob Chemother. 2018 Apr 1;73(4):1104-1106. doi: 10.1093/jac/dkx496.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Azabicyclo Compounds / adverse effects
  • Azabicyclo Compounds / therapeutic use*
  • Aztreonam / adverse effects
  • Aztreonam / therapeutic use*
  • Ceftazidime / adverse effects
  • Ceftazidime / therapeutic use*
  • Cross Infection / drug therapy
  • Cross Infection / epidemiology
  • Cross Infection / microbiology
  • Disease Outbreaks
  • Drug Combinations
  • Drug Therapy, Combination / adverse effects
  • Drug Therapy, Combination / methods
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Female
  • Hospitals
  • Humans
  • Klebsiella Infections / drug therapy*
  • Klebsiella Infections / epidemiology
  • Klebsiella Infections / microbiology
  • Klebsiella pneumoniae / enzymology*
  • Klebsiella pneumoniae / genetics
  • Klebsiella pneumoniae / isolation & purification
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Retrospective Studies
  • Spain / epidemiology
  • Treatment Outcome
  • beta-Lactam Resistance*
  • beta-Lactamase Inhibitors / adverse effects
  • beta-Lactamase Inhibitors / therapeutic use*
  • beta-Lactamases / genetics

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • beta-Lactamase Inhibitors
  • Ceftazidime
  • beta-lactamase CTX-M-15
  • beta-Lactamases
  • beta-lactamase NDM-1
  • oxacillinase
  • Aztreonam